156 related articles for article (PubMed ID: 23714071)
21. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice.
Chen L; Tang XD; Yu ST; Ai ZH; Fang DC; Cai YG; Luo YH; Liang GP; Yang SM
J Pathol; 2009 Apr; 217(5):685-92. PubMed ID: 19142972
[TBL] [Abstract][Full Text] [Related]
22. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
[TBL] [Abstract][Full Text] [Related]
23. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients.
Titu LV; Loveday RL; Madden LA; Cawkwell L; Monson JR; Greenman J
Oncol Rep; 2004 Oct; 12(4):871-6. PubMed ID: 15375515
[TBL] [Abstract][Full Text] [Related]
25. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
[TBL] [Abstract][Full Text] [Related]
27. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
28. In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells.
Kryukov F; Ocadlíková D; Kovárová L; Buresová I; Hájek R; Michálek J
J Immunotoxicol; 2009 Dec; 6(4):243-8. PubMed ID: 19908943
[TBL] [Abstract][Full Text] [Related]
29. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.
Vonderheide RH; Schultze JL; Anderson KS; Maecker B; Butler MO; Xia Z; Kuroda MJ; von Bergwelt-Baildon MS; Bedor MM; Hoar KM; Schnipper DR; Brooks MW; Letvin NL; Stephans KF; Wucherpfennig KW; Hahn WC; Nadler LM
Cancer Res; 2001 Dec; 61(23):8366-70. PubMed ID: 11731409
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
31. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
32. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
33. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
34. [CTLs induced by hTERT-related multiepitope peptide-sensitived mDCs specifically kill HLA-A24+ tumor cells].
Shen HP; Niu BL; DU HM; Zou LQ; Gong JP
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jun; 27(6):626-30. PubMed ID: 21651861
[TBL] [Abstract][Full Text] [Related]
35. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
36. The immunogenicity of the hTERT540-548 peptide in cancer.
Wenandy L; Sørensen RB; Sengeløv L; Svane IM; thor Straten P; Andersen MH
Clin Cancer Res; 2008 Jan; 14(1):4-7. PubMed ID: 18172245
[TBL] [Abstract][Full Text] [Related]
37. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
38. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
39. [Epitopic multiple antigen peptide from α-fetoprotein elicit antitumor immune response in vitro and ex vivo].
Fan ZJ; Zhang SR
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1138-42. PubMed ID: 22781777
[TBL] [Abstract][Full Text] [Related]
40. Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?
Speiser DE; Cerottini JC; Romero P
Cancer Immun; 2002 Oct; 2():14. PubMed ID: 12747759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
